August 17, 2012

Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


August 13, 2012

Pfizer will be the next consumer healthcare company to reach the market with a switched proton-pump inhibitor.

August 9, 2012

AstraZeneca paid $3.2 billion to Amylin Pharmaceuticals Thursday following the latter's acquisition by Bristol-Myers Squibb, AstraZeneca and Bristol said.

August 3, 2012

AstraZeneca's biologics division has begun shipping doses of influenza vaccine to distributors for the 2012-2013 flu season, the company said.

August 1, 2012

The Food and Drug Administration has approved a generic drug designed to treat asthma in children.

July 31, 2012

A drug made by Bristol-Myers Squibb and AstraZeneca improved several measures of blood-sugar control in Type 2 diabetes patients at high risk of cardiovascular disease, according to results of a late-stage clinical trial announced Monday.

July 2, 2012

Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

June 19, 2012

AstraZeneca and Rigel Pharmaceuticals have entered an exclusive worldwide license agreement for the global development and commercialization of an investigational treatment for moderate to severe chronic asthma.

May 15, 2012

The head of drug maker AstraZeneca will retire next month, the company said.

April 23, 2012

Anglo-Swedish drug maker AstraZeneca will buy a San Diego-based biotech company for $1.26 billion, the two said Monday.

April 12, 2012

AstraZeneca has launched a new drug for treating high blood pressure, the company said Thursday.

March 28, 2012

Three companies have launched generic versions of a psychiatric drug made by AstraZeneca following a court decision turning down the Anglo-Swedish drug maker's request for an injunction against the Food and Drug Administration's approval of the generics.

March 26, 2012

A federal court has dismissed a case that drug maker AstraZeneca filed against regulators regarding a drug used to treat psychotic and bipolar disorders, the company said Monday.

February 28, 2012

Drugs widely used to treat cholesterol may cause increases in blood sugar and other symptoms, the Food and Drug Administration said Tuesday.

February 9, 2012

The National Association for Female Executives on Wednesday released its list of the "Top 50 Companies for Executive Women."

February 8, 2012

An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

February 1, 2012

Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

January 24, 2012

In an effort to help chronically ill Americans that rely on safety net clinics for their medical care, AstraZeneca has donated $3.8 million worth of prescription medicines to AmeriCares.

January 19, 2012

The Food and Drug Administration has declined to approve a drug for Type 2 diabetes made by Bristol-Myers Squibb and AstraZeneca, saying it needs additional clinical data, the companies said Thursday.

January 18, 2012

Patent expirations of key blockbuster drugs and efforts by payers to contain costs are likely to bring strong growth to the global generic drug market in the next few years as market-earned revenues grow by more than $100 billion, according to an analysis by research firm Frost & Sullivan.

December 20, 2011

AstraZeneca and Targacept released results of the second of four phase-3 clinical trials that investigated the efficacy and tolerability of a drug that could serve as an adjunct therapy to major depressive disorder patients that had an inadequate response to initial antidepressant therapies.

December 19, 2011

The Food and Drug Administration has approved a drug for treating high blood pressure made by Mylan, FDA records showed.

December 15, 2011

A study conducted by Bristol-Myers Squibb and AstraZeneca found that adding an investigational compound to an existing Type 2 diabetes treatment may help reduce blood-glucose levels among patients.

November 17, 2011

Bristol-Myers Squibb and AstraZeneca presented an analysis Wednesday of 14 clinical trials at the American Heart Association's Scientific Sessions in Orlando, Fla., the companies said.